Berberine Pharmacology in Metabolic and Cancer Therapeutics

Berberine is a plant‐derived isoquinoline alkaloid with a broad pharmacological spectrum that spans metabolic regulation and anticancer activity. In metabolic disorders, berberine improves glycaemic control and lipid profiles by activating cellular energy sensors and modulating key enzymes. Central to its action is the stimulation of AMP‐Activated Protein Kinase, which enhances glucose uptake, inhibits hepatic gluconeogenesis and suppresses lipogenesis. Limited oral bioavailability has stimulated research into microbial conversion of berberine into more absorbable derivatives, thereby improving systemic exposure and therapeutic efficacy. In oncology, berberine exerts cytostatic and cytotoxic effects across diverse tumour types through cell‐cycle arrest, induction of apoptosis and inhibition of metastatic processes. These effects are mediated by modulation of signalling pathways including NF-κB, PI3K/Akt and MAPK, as well as epigenetic mechanisms. Synergies with chemotherapeutic agents have emerged in preclinical models, reinforcing its potential as an adjuvant. Together, these multifaceted mechanisms underscore the global significance of berberine as a lead compound for novel therapies in cardiometabolic diseases and cancer.

Research from Nature Portfolio

Recent studies have identified a crucial role for the gut microbiota in transforming orally administered berberine into dihydroberberine, a reduced form with markedly enhanced intestinal absorption. This microbial conversion increases plasma concentrations of the active alkaloid and amplifies its lipid- and glucose-lowering effects in models of metabolic syndrome. Restoration of microbial nitroreductase activity has been shown to directly correlate with therapeutic outcomes, highlighting the interplay between host microbiome and drug bioavailability.

Berberine Pharmacology in Metabolic and Cancer Therapeutics publication trend

The graph below shows the total number of articles in berberine pharmacology in metabolic and cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

AMP-Activated Protein Kinase (AMPK): A cellular energy sensor that, when activated, promotes catabolic pathways generating ATP and inhibits energy-consuming anabolic processes.

Nuclear factor kappa B (NF-κB): A transcription factor complex that regulates genes involved in inflammation, immunity and cell survival, often aberrantly activated in metabolic and neoplastic diseases.

Dihydroberberine (dhBBR): The reduced form of berberine generated by gut microbial nitroreductases, exhibiting enhanced intestinal uptake and subsequent reoxidation to berberine in tissues.

Mitochondrial respiratory complex I: The first enzyme complex in the electron transport chain that transfers electrons from NADH to ubiquinone, inhibition of which can alter cellular energy balance.

References

1. Acetylation of p65Lys310 by p300 in macrophages mediates anti-inflammatory property of berberine. Redox Biology (2023).
2. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I A Mechanism for the Action of Berberine to Activate AMP-Activated Protein Kinase and Improve Insulin Action. Diabetes (2008).
3. Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis. PLOS ONE (2011).
4. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. Journal of Lipid Research (2006).
5. Transforming berberine into its intestine-absorbable form by the gut microbiota. Scientific Reports (2015).
6. Berberine, an Epiphany Against Cancer. Molecules (2014).
7. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics (2019).